Phase II study of E7070 in patients with metastatic melanoma.
E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma.
Smyth
J F
JF
University of Edinburgh, Cancer Research Centre, Western General Hospital, Edinburgh, UK. john.smyth@cancer.org.uk
Aamdal
S
S
Awada
A
A
Dittrich
C
C
Caponigro
F
F
Schöffski
P
P
Gore
M
M
Lesimple
T
T
Djurasinovic
N
N
Baron
B
B
Ravic
M
M
Fumoleau
P
P
Punt
C J A
CJ
D000328:Adult; D000368:Aged; D018450:Disease Progression; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
C439829:N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide; D013449:Sulfonamides